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Abstract 
Cytochrome P450 enzymes are increasingly investigated due to their potential application as 
biocatalysts with high regio- and/or stereo-selectivity and under mild conditions. Vitamin D3 
metabolites are of pharmaceutical importance and are applied for the treatment of vitamin D3 
deficiency and other disorders. However, the chemical synthesis of vitamin D3 derivatives shows low 
specificity and low yields. In this study, cytochrome P450 CYP109A2 from Bacillus megaterium 
DSM319 was expressed, purified and shown to oxidize vitamin D3 with high regio-selectivity. The in 
vitro conversion, using cytochrome P450 reductase (BmCPR) and ferredoxin (Fdx2) from the same 
strain, showed typical Michaelis-Menten reaction kinetics. A whole-cell system in B. megaterium 
overexpressing CYP109A2 reached 76 ± 5% conversion after 24h and allowed to identify the main 
product by NMR analysis as 25-hydroxylated vitamin D3. Product yield amounted to 54.9 mg L
-1 day-
1, rendering the established whole-cell system as a highly promising biocatalytic route for the 
production of this valuable metabolite. The crystal structure of substrate-free CYP109A2 was 
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CYP109A2 uses a highly similar set of residues for vitamin D3 binding as the related vitamin D3 
hydroxylases CYP109E1 from Bacillus megaterium and CYP107BR1 (Vdh) from Pseudonocardia 
autotrophica. However, the folds and sequences of the BC loops in these three P450s are highly 
divergent, leading to differences in the shape and apolar/polar surface distribution of their active site 
pockets, which may account for the observed differences in substrate specificity and the regio-
selectivity of vitamin D3 hydroxylation.  
 
Introduction 
Vitamin D3 (VD3) is a secosteroid that is produced in the human skin from the precursor 
compound 7-dehydrocholesterol upon exposure to UV light irradiation, resulting in the opening of the 
precursor B-ring. Afterwards, VD3 is metabolized successively in the liver and kidneys to form two 
derivatives that are highly important for human health, the 25-hydroxyvitamin D3 (25(OH)VD3) and 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2VD3, Figure 1). While the latter derivative is the biologically 
active form of VD3, the former one is the most abundant circulating metabolite of VD3 in the blood 
and is therefore considered to be an optimal indicator of the nutritional status concerning VD3 in 
patients [1,2]. Maintaining an optimal level of 25(OH)VD3 is crucial for reducing the risk of several 
chronic diseases or cancer conditions [3]. Moreover, the 25(OH)VD3 metabolite is acknowledged for 
better absorption properties as compared to VD3 in certain supplement-based treatments [4,5]. 
Unfortunately, chemical synthesis of VD3 derivatives is a challenging, multistep procedure resulting 
in low product yields, limiting their usefulness as therapeutic dietary supplements [6]. 
Biotechnological approaches involving enzymes capable of specifically oxidizing VD3 offer an 
attractive alternative to circumvent such limitations.   
In humans, the two consecutive VD3 hydroxylation steps, at carbons C-25 and C-1, are 
catalyzed by proteins belonging to the cytochrome P450 superfamily (P450s or CYPs) [7]. The P450s 
are heme-containing enzymes that catalyze the monooxygenation of a large variety of organic 
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metabolism of xenobiotics and drugs. Considering the broad range of P450 substrates, the enzymes 
are of benefit to synthesis of pharmaceutically and biotechnologically valuable compounds, in 
particular when high regio- and stereo-selectivity of hydroxylation is required. Microbial P450s are 
favored, as they are soluble and more stable than their eukaryotic counterparts [8-10]. Thus far, only a 
few bacterial P450 enzymes have been reported that hydroxylate VD3 to produce the desired 
25(OH)VD3 metabolite, like CYP105A1 from Streptomyces griseolus [11] or CYP107BR1 (Vdh) 
from Pseudonocardia autotrophica [12]. Most recently, our investigations led to the identification and 
characterization of another bacterial VD3-hydroxylase, cytochrome P450 CYP109E1 from Bacillus 
megaterium DSM319 [13]. The improvement of activity and/or regio-selectivity of the three above-
mentioned enzymes by protein engineering was supported by the knowledge of their structure-
function relationships, thanks to determination of their crystal structures in both the open, substrate-
free and closed, substrate-bound states [14-18].  
Here we describe the identification and analysis of a new cytochrome P450 enzyme from 
Bacillus megaterium DSM319, classified as CYP109A2, which shares 45% amino acid sequence 
identity with CYP109E1. Similar to CYP109E1, CYP109A2 exhibits 25-hydroxylation activity 
towards VD3, however, with significantly higher regio-selectivity. A whole-cell B. megaterium-based 
VD3 oxidation system was established for CYP109A2 and resulted in higher yields of 25(OH)VD3 as 
compared to the previously reported most productive variant of CYP109E1, i.e., mutant I85A [13]. 
The three-dimensional structure of CYP109A2 was obtained by X-ray crystallography and compared 
to the structures of other bacterial P450s that convert VD3, suggesting putative structural features 
associated with differences in substrate specificity and regio-selectivity.   
 
Results and Discussion  
Identification, sequence analysis and initial characterization of CYP109A2   
Bioinformatic mining of the Bacillus megaterium DSM319 genome previously led to identification of 
four genes putatively encoding for cytochrome P450 enzymes (CYP102A1, CYP106A1, CYP109E1 
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in detail yet. Its open reading frame (KEGG: BMD_2035) encodes for a 403 amino acid long protein 
containing three characteristic sequence motifs, which support its annotation as a P450 enzyme: (i) 
heme-binding domain signature proceeding the L helix (FxxGx(H/R)xCxG), (ii) the acid-alcohol pair 
in the I helix (Glu244, Thr245) and (iii) ExxR motif in the K helix (Figure 2). Interestingly, 
CYP109A2 shares 45% sequence identity with CYP109E1 from the same organism (the sequence 
identity with CYP106A1 and CYP102A1 is 36% and 24%, respectively). Comparative sequence 
analysis including proteins from different bacterial sources further shows that CYP109A2 shows 
significant sequence homology to VD3 hydroxylating P450s from the CYP107 and CYP105 family 
(37% identity to CYP107BR1 (Vdh) from P. autotrophica, 36% to CYP107CB2 from B. lehensis G1, 
32% identity to CYP105A1 from Streptomyces griseolus and 30% to CYP105A2 from P. 
autotrophica). Residues in CYP109A2 with the highest degree of conservation have a role in heme 
binding or belong to substrate recognition site 4 (SRS4) (central part of I helix), whose residues have 
common roles in P450s associated with substrate binding, oxygen activation and proton delivery 
during catalysis [20]. Other regions associated with substrate binding (SRS2, SRS5 and SRS6) are 
less well conserved, although relatively higher conservation levels may be observed in SRS5 or SRS6 
upon pairwise comparison of P450s belonging to the same CYP family, like CYP109A2 and 
CYP109E1. The lowest degree of conservation is displayed by the amino acids belonging to SRS1 
(the BC loop region) and SRS3 (the G helix) (Figure 2).  
Since a significant sequence similarity between bacterial P450s belonging to the same CYP 
family may correlate to similarities in substrate scope [21], we set out to establish whether VD3, being 
a substrate for CYP109E1, is also converted by CYP109A2. To produce sufficient amounts of pure 
and functional CYP109A2 enzyme for the intended functional analysis, the cyp109a2 gene was 
cloned into the pET17b vector and expressed in E. coli C43 (DE3) cells with high yield (4210 
nmol*L-1). The protein was purified by affinity chromatography and displayed characteristic P450 
spectroscopic behavior, considering both the UV-visible spectrum of its oxidized ligand-free and 
reduced CO-bound forms (Figure 3). Spectroscopic analysis thus confirmed that the purified protein 
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CYP109A2 catalyzes regio-selective oxidation of vitamin D3 in vitro   
Cytochromes P450 are external monooxygenases and thus require electrons for their catalytic activity 
from different (autologous or heterologous) redox partners [22]. Selection of suitable redox partners 
to support CYP109A2 activity was based on previous observations that B. megaterium cytochrome 
P450 reductase (BmCPR) and a ferredoxin (Fdx2) were able to support CYP106A1 with much higher 
efficiency than the commonly used AdR-Adx4-108 (adrenodoxin reductase – adrenodoxin) redox 
partners [23]. Indeed, reconstitution of CYP109A2 activity was accomplished using both redox 
partner systems, but the CYP109A2-catalysed in vitro reactions (200 µM, 1h) yielded a significantly 
higher VD3 conversion ratio when using the BmCPR-Fdx2 redox pair (36 ±4 %) (Figure 4A) as 
compared to the AdR-Adx4-108 pair (20 ± 5 %, data not shown). Usage of the different redox pairs 
(BmCPR-Fdx2 or AdR-Adx4-108) to reconstitute CYP109A2 activity towards VD3 resulted in identical 
product patterns, showing one main product P1 (~ 64% of total products) and one minor product P2 (~ 
36% of total products) (Figure 4A). Determination of the steady-state kinetics of VD3 conversion by 
CYP109A2 showed a typical Michelis-Menten behavior with kcat nd KM values of 3.42 ± 0.15 min
-1 
and 49.0 ± 5.8 µM, respectively (Figure 5). These results demonstrate that the CYP109A2 in vitro 
activity towards VD3 is lower than that of other previously characterized bacterial VD3 hydroxylases 
[24]. In addition, CYP109A2 displays a lower substrate conversion ratio in comparison to its most 
closely related homolog CYP109E1, which was shown to convert ~90 % of VD3 under the same 
conditions (when supported by the AdR- Adx4-108 pair) [13]. The affinity for VD3 is also lower in 
CYP109A2 as compared to wild type CYP105A1 or Vdh, which showed KM values of 0.54 ± 0.09 µM 
and 13.5 ± 3.7 µM, respectively [12,25].    
 
On the other hand, the regio-selectivity of CYP109A2, as evident from its product pattern of 
VD3 conversion, is superior to that of the other bacterial VD3 hydroxylases. CYP109A2 converts VD3 
into two products only, whereas previously it was shown that CYP109E1 converts the same substrate 
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25-hydroxylase CYP105A2 from P. autotrophica the exact product profile is not yet determined [24]. 
Interestingly, upon comparison of the CYP109A2 product retention times with the available authentic 
standards and HPLC data previously obtained for CYP109E1, it was hypothesized and later shown 
(see below) that product P1 is 25-hydroxyvitamin D3. Therefore, to the best of our knowledge the 
newly identified enzyme, CYP109A2 from B. megaterium, is the most regio-selective bacterial VD3 
hydroxylase characterized so far.  
 
Whole-cell based bioconversion of vitamin D3 by CYP109A2 
Our recent study of CYP109E1 has demonstrated that the B. megaterium-based whole cell system 
may be an efficient and sustainable route to large-scale production of VD3 metabolites like 
25(OH)VD3 [13]. Bacillus megaterium is a Gram-positive, non-pathogenic bacterium and a well-
studied biotechnologically applicable production host. Its use in the pharmaceutical and food 
industries is preferred thanks to the ability of this bacterium to grow on a variety of carbon sources 
and simple media as well as due to its high protein production capacity and plasmid stability [26,27]. 
Importantly, as shown by research results considering various P450 enzymes, the B. megaterium 
offers certain advantages, of being not only a source of new, uncharacterized P450s but also a very 
good host for P450s and/or their homologous or heterologous redox partners [19,28-30]. Use of the 
whole-cell expressed P450(s) in a biotransformation process allows for regeneration of the expensive 
NADPH cofactor that is necessary for P450 activity.  
 
The B. megaterium MS941 cells were transformed with expression plasmid 
pSMF2.1.CYP109A2, and using such a system 76 ± 5% of 200 µM VD3 was successfully converted 
within 24 h into one main product P1 (90%) and one minor product P2 (10%) (Figure 4B). In 
comparison to the profile observed in vitro the product ratio obtained in vivo is slightly changed, 
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most probably caused by the fact that no heterologous redox partners were expressed along with 
CYP109A2, leaving only the endogenous B. megaterium redox proteins (which remain to be 
identified) to support its activity. In fact, it was recently observed that varying the redox partners for 
reconstitution of P450-based reactions can influence the observed product ratios [31,32].  
 
Product isolation and identification by nuclear magnetic resonance analysis 
As for the in vitro conversion of VD3 by CYP109A2, the main hydroxylated product obtained by the 
in vivo conversion showed an identical retention time in HPLC analysis as the authentic standard of 
25-hydroxyvitamin D3. To allow full characterization of the product(s) by nuclear magnetic resonance 
spectroscopy (NMR), the in vivo reactions were up-scaled to 400 ml of total culture volume (200 µM 
VD3), and thus 16 mg of the product of interest (P1) were obtained. Unfortunately, the yields of 
product P2 were not sufficient to allow for the direct product identification by NMR. For the isolated 
product P1 the 1H NMR and 13C NMR spectra were recorded. It was observed that in comparison to 
standard VD3, product P1 showed resonances for an additional tertiary hydroxyl group (at C-25) in 
the 13C NMR spectrum (δC 71.15), whereas the resonances of the methyl groups C-26 and C-27 both 
 ppe red  s s  g ets (δH 1.19 s, 6H) in the 
1H NMR spectrum. This clearly indicated that CYP109A2 
catalyzes conversion of VD3 to 25(OH)VD3 as the main product (Figure 6). The NMR data are in 
accordance with reported literature (Table S1) [33,34].   
 
Efficient biocatalytic production of 25-hydroxyvitamin D3 by CYP109A2 
Based on the results of the in vivo conversion of VD3 performed by the CYP109A2-based whole-cell 
system, the yield of 25(OH)VD3 was calculated to be 54.9 mg L
-1 day-1. Hence, it becomes apparent 
that the production yield of the CYP109A2-based whole-cell system is significantly higher as 
compared to other bacterial in vivo CYP-based systems known to produce the same product. For 
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and reaction time produced 24.5 mg L-1 day-1 of 25(OH)VD3, whereas with its best mutant I85A, the 
achieved yield was 45 mg L-1 day-1 [13]. The yield achieved with the CYP109A2-based system is also 
higher than the yield reported for the most productive mutant of CYP105A1 (R73A/R84A), which 
produced 7.8 mg 25(OH)VD3 L
-1 day-1 [14]. Only Vdh expressed in A. autotrophica (now referred to 
as P. autotrophica) was reported to give a higher yield than CYP109A2 being 137 mg L-1 [35]. 
However, this value was obtained after 72 h, whereas, in case of CYP109A2 described here 54.9 mg 
L-1 were obtained already after 24 h. Thus, the B. megaterium CYP109A2-based whole-cell system 
offers a very promising biotechnological alternative to production of 25-hydroxyvitamin D3 in 
comparison to other characterized P450 biocatalysts.    
 
Crystal structure of substrate-free CYP109A2  
In order to determine the geometry of its active site pocket and predict the residues responsible for 
VD3 binding, the CYP109A2 enzyme was studied by X-ray crystallography. For crystallization, a C-
terminally His-tagged protein was purified using the previously described three-step purification 
procedure, resulting in protein sample of >98% purity and low polydispersity (12.2 %) as confirmed 
by SDS-PAGE analysis and dynamic light scattering measurements (data not shown). The substrate-
free CYP109A2 crystallized in an orthorhombic space group (P212121), with four monomers in the 
asymmetric unit and a solvent content of 50%. The crystal structure was solved at 2.7 Å resolution by 
the molecular replacement method, using the previously determined structure of CYP109E1 
(sequence similarity 45%, PDB entry 5L90, [18]) as a search model (see Table 1 for data collection 
and refinement statistics). All four CYP109A2 molecules have well defined electron density, except 
for the fifteen or sixteen N-terminal residues and the C-terminal His6-tags, for which no electron 
density was observed. The central parts of the BC loop, FG loop and N-terminal end of the G helix 
show relatively high B factors, related to high mobility of those regions, as generally observed in 
P450 crystal structures. The four CYP109A2 molecules found in the asymmetric unit have almost 
 de t c   c  f rm t   s (the r  t me   squ re dev  t    [r m s d]  f Cα-backbone atoms ranges 
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structure of CYP109A2 (residues 16-401) exhibits the typical organization of a P450 domain, 
containing fifteen helices (labeled A-L, A’, B’   d  ’),   d te  β-str  ds ( rr  ged    three β-sheets; 
in the same structural arrangement as observed in the CYP109E1 crystal structure, Figure 7A). The 
centrally located heme group is sandwiched between the I and L helices, similarly as in other P450s. 
The bound heme is covalently attached to the protein by an iron-sulfur bond with Cys351, and is 
further stabilized by several residues providing van der Waals and hydrophobic interactions, while its 
propionate side chains interact with the side chains of His91, Arg95, Arg293 and His349. At the distal 
side of the heme, no clear electron density was observed for a heme-bound water molecule, in contrast 
to many other P450 crystal structures determined in the substrate-free state. A small blob of electron 
density is located at approximately 5 Å distance from the heme-iron, which may correspond to a 
glycerol molecule from the cryo-buffer, but the quality of the electron density did not allow 
unambiguous ligand identification. In addition, five PEG 400 molecules and three sulfate ions (SO4
2-), 
originating from the crystallization solution, are present in the structure.  
 
Structural comparison of CYP109A2 overall fold and active site architecture with related 
vitamin D3 hydroxylases 
CYP109A2 cryst    zed       ‘ pe ’ c  f rm t   , which is confirmed by structural alignments 
against other P450 structures deposited in the Protein Data Bank (PDB), giving the best match to 
those displaying open active site geometry (Table S2). The highest structural similarity is observed 
with the ‘ pe ’ crystal structure of CYP109E1 containing four bound corticosterone molecules in the 
active site pocket (PDB entry 5L91, r m s d   f 1 27 Å f r 368 Cα  t ms). In addition, a significant 
structural similarity is observed with the structures of Vdh from P. autotrophica, considering both its 
wild type and its mutant forms (L348M and F106V) [36] (e.g. wild type Vdh, PDB entry 3A4G, 
r m s d   f 1 44 Å f r 349 Cα  t ms). Visual analysis of the CYP109A2, CYP109E1 and Vdh 
structures shows that they contain similar, wide-open, funnel-sh ped   d s  ve t exp sed ‘d st  ’ 
heme pockets. The main difference concerns the BC loop/SRS1 region (loop connecting the B and C 
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structures of the three different enzymes (Figures 2 and 7B). CYP109A2 contains the shortest BC 
loop, whereas the longest loop is present in Vdh (Figure 2). While the BC loop in CYP109A2 folds 
towards the active site pocket, the loops in CYP109E1 and especially Vdh are folded more outwards 
(Figures 7B and 8A). As a result, the BC loop in CYP109A2 restricts access of substrate to the 
heme-iron to a larger extent than the BC loops in CYP109E1 and Vdh. The structural differences in 
the BC loop region further result in a striking difference in the distribution of hydrophobic and polar 
regions in the active sites of the three P450s (Figure 8B, C and D). In the region closest to the heme, 
the active site pockets in CYP109A2, CYP109E1 and Vdh display a similar, mainly apolar surface 
due to the presence of conserved hydrophobic residues, i.e., Leu84, Met85 (SRS1); Leu237, Val240, 
Ala241 (SRS4); Ile288, Ile291 (SRS5) and Phe389, Val390 (SRS6) in CYP109A2. A bit further away 
from the heme, however, the surfaces show some significant differences. Residues Arg74, Glu78, 
Arg79 and Glu81 of the BC loop in CYP109A2 form a highly polar surface restricting one side of the 
active site pocket (Figure 8B). In the active site pocket of CYP109E1 the BC loop also forms a polar 
surface, but it is much less pronounced as in CYP109A2 (Figure 8C), while in Vdh it is nearly absent 
(Figure 8D). The observed differences in BC loop geometry, in the extent of restricted access to the 
heme-iron and in the apolar/polar surface distribution around the active site pocket will likely 
influence the substrate binding modes in the three different enzymes. In the absence of a closed, VD3-
bound crystal structure of CYP109A2 it remains unknown whether these differences are directly 
related to the differences in regio-selectivity for VD3 hydroxylation. Arguably, a significantly more 
polar BC loop region and a more constricted active site pocket in CYP109A2, in comparison to 
CYP109E1 or Vdh, allows for lower occurrence of differently stabilized VD3 binding modes, 
therefore resulting in an increased regio-selectivity of substrate hydroxylation in comparison to 
CYP109E1 or Vdh, as observed experimentally. Indeed, the BC loop, a highly variable and flexible 
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Prediction of vitamin D3 binding residues in CYP109A2 
Unfortunately, our experiments to crystalize a structure of CYP109A2 in its closed conformation were 
not successful, despite extensive efforts to obtain a structure of substrate-bound and/or product-bound 
CYP109A2. The residues known or predicted to bind and stabilize VD3 in the active sites of 
CYP109E1 or Vdh were therefore compared to their structural equivalents in CYP109A2 (Table 2). 
Based on this comparison the following thirteen residues of CYP109A2 are predicted to interact with 
VD3: Arg74, Leu84, Met85 from SRS1; Leu167, Val168 from SRS2; Arg186, Asn187, Val190 from 
SRS3; Leu237, Val240, Thr245 from SRS4; Ile291 from SRS5 and Phe389 from SRS6 (Figure 9). Of 
these residues, six are identical to those in CYP109E1 or Vdh, while the other residues are relatively 
similar. This significant degree of conservation further supports the notion that the overall binding 
mode of VD3 leading to 25-hydroxylation is similar in these enzymes. Whether the predicted residues 
in CYP109A2 indeed have important roles in substrate binding and conversion has to await further 
analysis by site-directed mutagenesis.  
 
In summary, we have shown that cytochrome P450 monooxygenase CYP109A2 from Bacillus 
megaterium is able to catalyze hydroxylation of vitamin D3 to its 25-hydroxylated derivative, with 
high regio-selectivity. The activity was reconstituted in the whole-cell based system, allowing to 
obtain high yields of the desired 25-hydroxylated product and therefore renders the system as most 
efficient and regio-selective in comparison to other related bacterial P450s previously shown to 
oxidize vitamin D3. These characteristics highlight the significance of CYP109A2 as a promising, 
potential industrially applicable biocatalyst. The crystal structure of CYP109A2 allowed for a detailed 
analysis of the active site geometry and prediction of VD3 interacting residues. Our study forms the 
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Experimental Procedures  
Materials 
VD3, 25(OH)VD3, (2-hydroxypropyl)-β-cyclodextrin and saponin (from quillaja bark) were purchased 
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany)   s pr py  β-D-1-thiogalactopyranoside 
(IPTG) and -aminolevulinic acid (-ALA) were purchased from Carbolution Chemicals GmbH 
(Saarbruecken, Germany). Bacterial media were purchased from Becton Dickinson (Heidelberg, 
Germany). All other chemicals were from standard sources and of highest purity available. The E. coli 
TOP10 strain used for cloning purposes was bought from Invitrogen, whereas the E. coli C43 (DE3) 
strain and pET17b (Merck Bioscience, Bad Soden, Germnay) vector used for heterologous expression 
were purchased from Novagen. The pSMF2.1 vector was used for protein expression in B. 
megaterium MS94 [38].  
 
Cloning 
The cyp109a2 gene (GenBank GeneID 9117426) was amplified by polymerase chain reaction (PCR) 
using genomic DNA of B. megaterium MS941 as template (mutant derived from DSM319 strain) 
[39,40]. To allow expression of CYP109A2 carrying a C-terminal His6-tag, the cyp109a2 gene was 
extended with a sequence at the 3`end coding for the desired tag and cloned into the expression vector 
pET17b with the NdeI/KpnI restriction sites yielding pET17b.CYP109A2. The primer pair used was 
5´-ATATCATATGAATCCAAAAGCAGT-GAAAAGAGAAAATCG-3´ and 5´-
TTAGGTACCTCAATGGTGGTGGTGATGATG-GGCGTTATTAAAAGCAATTTC-3´. The 
cyp109a2 gene was also cloned into the pSMF2.1 vector using PacI/SpeI restriction sites and 
including an optimized ribosomal binding site for B. megaterium, yielding pSMF2.1.CYP109A2. The 
primer pairs used were 5´-
CGCTTAATTAAAAATCAAGGAGGTGAATGTACAATGAATCCAAAAGCAGTGAAAAGAG-
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Heterologous gene expression and purification 
The E. coli C43 (DE3) cells serving as expression host were transformed with the 
pET17b.CYP109A2 construct and cultured overnight in Luria-Bertani (LB) medium containing 100 
μg mL-1 ampicillin, at 37 °C and 140 rpm. The overnight culture was used to inoculate a 250 mL main 
culture (Terrific Broth (TB) medium) conta    g 100 μg mL-1 ampicillin. The main culture was grown 
at 37 °C and 140 rpm until the optical density at 600 nm reached 0.6. Gene expression was induced by 
addition of 1 mM IPTG and 0.5 mM -ALA (heme precursor). The culture was further grown at 30 
°C (120 rpm) for 24 h. The E. coli cells were harvested by centrifugation at 4,500 rpm for 30 min, and 
ce   pe  ets  ere st red  t − 20 °C u t   pur f c t     F r b  chem c   ch r cter z t   , the pr te     s 
purified using a simplified procedure (one-step immobilized metal ion affinity chromatography). For 
crystallization, a three-step purification protocol was followed, as described previously (ion exchange 
chromatography, gel filtration, mixed-mode ion exchange chromatography) [18]. Purification of the 
redox partner protein pairs (BmCPR-Fdx2 and AdR-Adx4-108) was performed according to the 
previously reported procedures [19,23].   
 
Protein quality analysis  
Spectroscopic properties of the purified P450 were analyzed using a double-beam spectrophotometer 
(UV-2101PC, Shimadzu, Japan). All UV-visible absorbance spectra were recorded from 200 to 700 
nm. Concentration of CYP109A2 was estimated based on CO-difference spectroscopy (using an 
extinction coefficient of 91 mm −1·cm−1), according to the method of Omura and Sato [41]. Protein 
purity and heterogeneity were analyzed by SDS-PAGE and dynamic light scattering (DLS), 
respectively. The dynamic light scattering measurement was performed using a DynaPro NanoStar 
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 In vitro conversion and kinetic analysis 
Enzymatic activity of CYP109A2 was reconstituted in an in vitro system containing 1 µM 
CYP109A2, 3 µM ferredoxin reductase (BmCPR or AdR), 20 µM ferredoxin (Fdx2 or Adx8-104), 1 
mM MgCl2, and a cofactor regenerating system with glucose-6-phosphate (5 mM) and glucose-6-
phosphate dehydrogenase (1 U), all in 50 mM potassium phosphate buffer containing 20% glycerol 
(pH 7.4) and at 250 µL final volume. VD3 was dissolved in (2-hydroxypropyl)-β-cyclodextrin (2.25%) 
and added at 200 µM final concentration. The reaction was started by addition of 0.5 mM NADPH at 
30 °C. After 1 h, the reaction was stopped and extracted twice with 500 µL of ethyl acetate. The 
organic phases were combined, evaporated to dryness and prepared for analysis by high-performance 
liquid chromatography (HPLC). For determination of kinetic parameters of VD3 conversion by 
CYP109A2, three independent in vitro reactions were performed (each continuing for 20 min). VD3 
concentrations ranged from 0 to 400 µM. The kcat and KM values were calculated by plotting the 
product formation rate against increasing substrate concentration. The data were fit to the Michaelis-
Menten equation using Origin software from OriginLab Corporation.  
 
High-performance liquid chromatography (HPLC) 
The HPLC analysis was carried out on a Jasco system (Pu-980 HPLC pump, AS-950 sampler, UV-
975 UV/visible detector, LG-980-02 gradient unit; Jasco, Gross-Umstadt, Germany) equipped with a 
reversed-phase Nucleodur 100-5 C18 column (125 x 4 mm; Macherey-Nagel, Düren, Germany). The 
column temperature was adjusted to 40 °C. The s mp es  ere d ss  ved    200 µL of acetonitrile. A 
linear gradient of 60–100% aqueous acetonitrile was applied for 15 min (1 mL· min-1 flow rate), 
followed by 100% acetonitrile for 15 min. The UV detection of the substrate and products was 
accomplished at 265 nm. Assuming that the absorption properties of the products did not differ from 
the substrate, the product formation was calculated as the relative peak area (area %) of the HPLC 
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Whole-cell conversion in B. megaterium MS941 
The whole-cell conversions were performed in B. megaterium MS941 cells transformed with the 
pSMF2.1.CYP109A2 construct using the polyethylene glycol-mediated protoplast transformation 
method [42]. Initial seed culture was prepared in LB medium (10 µg·mL-1 tetracycline). The main 
culture (50 mL TB medium, 10 µg·mL-1 tetracycline) was inoculated with 500 µL of the seed culture 
(dilution 1:100) in 300 mL baffled flasks and incubated under shaking at 37 °C (140 rpm). The culture 
was grown to OD578 of 0.4 and at that point the recombinant gene expression was induced with xylose 
(5 mg·mL-1). The culture was further grown at 30°C for 24h (140 rpm). To initialize the whole-cell 
conversion experiments, after 24 h of protein expression the substrate (200 µM VD3 dissolved in 45% 
(2-hydroxypropyl)-β-cyclodextrin)) and a membrane-solubilizing agent (4% Quillaja Saponin) were 
added to the cultures. Afterwards the conversions were allowed to proceed at 30 °C and 120 rpm for 
24 h. Finally, 500 µL samples of the cultures were taken, extracted and prepared for HPLC analysis.  
 
Product isolation and NMR characterization  
In order to obtain sufficient amounts of the reaction product, the whole-cell based cultivation and 
conversion experiments were scaled up to 400 mL (2 x 200 mL) and performed as described above. 
The main reaction product (P1) was isolated and purified by reversed-phase HPLC using a preparative 
column VP Nucleodur 100-5 C18 (8.0 x 250 mm, Macherey-Nagel, Düren, Germany). The NMR 
spectra were recorded in CDCl3 with a Bruker Avance 500 NMR spectrometer at 298 K. The 
chemical shifts were relative to CHCl3  t δ 7 26 (
1H NMR) and CDCl3  t δ 77 00 (
13C NMR) using the 
st  d rd δ   t t       p rts per m        The 1D NMR (1H and 13C NMR) and the 2D NMR spectra 
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Crystallization, data collection and structure determination 
Aliquots with purified CYP109A2 were thawed, buffer exchanged to 20 mM Tris/HCl, pH 8.0, 0.1 
mM dithioerythritol and concentrated to 40 mg·mL-1 by ultrafiltration using a 30-kDa cutoff 
membrane. Crystallization condition screening was done in 96-well plate format. Sitting-drop vapor-
diffusion experiments were set up by a Mosquito crystallization robot (TTP LabTech), using 
commercially available high-throughput crystallization screens. Multiple hits were obtained overnight 
and the most promising condition (2.0 M ammonium sulfate, 0.1 M HEPES, pH 7.5, and 2% (v/v) 
PEG 400) was chosen for further optimization. Crystal optimization was performed manually at 293 
K by the sitting-drop vapour diffusion method in 24-well plates using reservoir solution volumes of 
300 μL  Pr te   dr ps  ere prep red by m x  g 1 μL  f pr te     d 1 μL  f reserv  r s  ut     A 
single, red plate-like crystal of CYP109A2 appeared after 3 days using a reservoir solution containing 
1.9 M ammonium sulfate, 0.1 M HEPES, pH 7.5, and 2% (v/v) PEG 400 and needed about a week to 
grow to its final dimensions (0.12 x 0.04 x 0.03 mm3). 
For data collection, the crystal was shortly swiped through a cryobuffer droplet (mother liquor 
supplemented with 30% (v/v) glycerol) and flash-cooled to 100 K in a cold nitrogen gas cryostream. 
X-ray diffraction data were collected at the ID23-2 beam line of the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France. Reflections were indexed and integrated using XDS [43], while 
scaling and merging of the data was done with AIMLESS from the CCP4 software suite [44]. The 
structure of CYP109A2 was determined by molecular replacement using Phaser from the PHENIX 
software package [45], applying the structure of substrate-free CYP109E1 (PDB entry 5L90, [18]) as 
a search model. The structure was completed with several cycles of model refinement using 
phenix.refine [46] alternated with manual model re-building using COOT [47]. At the final stages of 
refinement and model building water molecules were added to the model based on positive difference 
electron density peaks and strict interaction criteria. The final model was validated with MolProbity 
[48]. The model coordinates and structure factors are deposited in the Protein Data Bank with 
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Sequence and structure analysis  
Protein sequences were compared using the Basic Local Alignment Search Tool (BLAST, NCBI). 
Substrate recognition sites (SRS) in CYP109A2 were identified by alignment with P450cam 
(WP_032492633) and followed a description defined by Gotoh [49]: SRS1: 71-87 (BC loop), SRS2: 
163-169 (C’ term     p rt  f F he  x), SRS3: 185-192 (N’ term     p rt  f G he  x), SRS4: 229-247 
(central part of I helix), SRS5: 284-293 (K-β5 c   ect   )   d SRS6: 384-392 (β9-β10 tur )  P  r  se 
structural alignments were done using PDBeFold [50]. Multiple sequence alignment was done with 
Clustal Omega [51] and the output figure was prepared with ESPript3 [52]. The GenBank accession 
codes for analyzed sequences are as follows: CYP109A2 from B. megaterium DSM319 
(WP_013082916), CYP109E1 from B. megaterium DSM319 (WP_013084555), CYP105A1 from 
Streptomyces griseolus (BAG50411), CYP105A2 from Pseudonocardia autotrophica (BAA05541), 
Vdh (CYP107BR1) from P. autotrophica (C4B644), CYP107CB2 from B. lehensis G1 (AIC83164).  
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Table 1. Crystallographic data collection and refinement statistics of CYP109A2.  
    CYP109A2 




Monomers in the AU 4 
 
Solvent content (%) 50 
 
Ligands 5 x PEG 400, 3 x sulfate ion 
Data collection 
 
Beamline (ESRF) ID23-2 
 
Wavelength (Å) 0.873 
 
Resolution range (Å) 52-2.70 (2.78-2.70)a 
 
Space group P212121 
 
Unit-cell parameters  
  
a, b, c (Å) 77.12 155.53 158.15 
  
α, β, γ, ° 90 90 90 
 
Observed reflections 287,529 (25,387) 
 
Unique reflections 51,368 (4,458) 
 
Multiplicity 5.6 (5.7) 
 
Completeness (%) 97.3 (98.5) 
 
< /σ( )> 12.4 (1.7) 
 
Rmerge (%) 0.10 (0.94) 
 Rp.i.m. 0.07 (0.63) 
 
CC (1/2) (%) 99.6 (52.3) 
Refinement 
 
Rwork (%) 22.4 
 
Rfree (%) 27.5 
 
R.m.s.deviation, bond lengths (Å) 0.018 
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Ramachandran plot statistics 
 
  
Most favoured (%) 95.6 
  
Allowed regions (%) 4.4 
  
Disallowed regions (%) 0 
  Molprobity overall score 1.49 
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Table 2. Identification of residues with predicted VD3 binding roles in CYP109A2, based on 
structural comparison to CYP109E1 and Vdh. (A) Residues of CYP109E1 previously predicted to 
interact with the VD3 molecule [13] and their structurally equivalent residues in CYP109A2. (B) VD3-
binding residues in the crystal structure of VD3-bound Vdh (PDB id: 3A50) [16] and their structurally 
equivalent residues in CYP109A2. Residues of CYP109A2 appearing in both panels are highlighted 
in blue. The residues of CYP109E1 studied previously by site-directed mutagenesis [13,18] are 
highlighted in grey. Conserved CYP109A2 residues are shown in bold.  
A 
Predicted VD3-binding 
residues               
CYP109E1 




 SRS1 Arg69 Arg74 
 
SRS1 Thr84  - 
Pro71  - 
 
Met86  - 
Thr78  - 
 
Ile88 Leu84 





SRS2 Leu171 Leu167 
Asn86 Met85 
 
SRS3 Lys180 Arg186 






SRS3 Asn191 Val190 
 
SRS4 Leu232 Leu237 








SRS5 Pro287 Ile291 
   
 
SRS6 Leu387 Phe389 
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Figure 1: The activation pathway of vitamin D3 in mammals. First, vitamin D3 undergoes a C-25 
hydroxylation resulting in the formation of 25(OH)VD3 (in the liver) followed by the second 
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Figure 2. Multiple sequence alignment of CYP109A2 and other bacterial P450s showing 25-
hydroxylation activity with VD3 or VD3 derivatives. Secondary structural elements are shown as in 
the crystal structure of CYP109A2. Conserved and similar residues are highlighted in red and yellow, 
respectively. Helices are labeled A-L. Residues in the six substrate recognition sites (SRS) are 
enclosed in black boxes. The characteristic P450 sequence motifs are in blue boxes: the heme-binding 
dom    s g  ture just bef re the L he  x, ce tr   p rt  f   he  x   th the h gh y c  served ‘ c d- 
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Figure 3. Spectroscopic properties of CYP109A2. (A) The UV-visible absorbance spectrum of the 
reduced CO-bound form of CYP109A2 showing the characteristic Soret peak at 450 nm. (B) The UV-
visible absorbance spectrum of ligand-free CYP109A2 d sp  y  g typ c   pe  s; γ ( t 417  m), α 
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Figure 4. HPLC analysis of CYP109A2-dependent VD3 conversion. (A) In vitro conversion. (B) 
Whole-cell conversion in B. megaterium. The products are labeled P1-P2. The authentic standard of 














Figure 5. Determination of the kinetic parameters of VD3 conversion catalyzed by CYP109A2. Mean 
values and standard deviations (error bars) were calculated from the results of three independent 
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Figure 7. Crystal structure of substrate-free CYP109A2. (A) Ribbon representation with secondary 
structure elements labeled following the common P450 nomenclature (rainbow coloring from blue N’ 
terminus to red C’ term  us)  He  ces  re   be ed A-L following the common P450 nomenclature of 
secondary structure elements. Heme is shown as red stick model. (B) Superposition of the overall 
open conformations of CYP109A2, CYP109E1 from B. megaterium DSM319 and Vdh from 
Pseudonocardia autotrophica. Cartoon representation of the aligned structures of CYP109A2 (green), 
CYP109E1 (5L90, blue) and Vdh (3A4G, pink) is shown.  
 
Figure 8. Comparison of the substrate binding pockets in CYP109A2, CYP109E1 from B. 
megaterium DSM319 and Vdh from Pseudonocardia autotrophica, all presenting an open 
conformation. (A) Three structures are superimposed and their molecular surfaces are shown in grey. 
The steric restriction of the active site pocket imposed by the BC loop region is significantly larger in 
the CYP109A2 structure (surface in green) than in CYP109E1 (5L90, in blue) and Vdh (3A4G, in 
magenta). (B-D) Surface representation of the ‘d st  ’ heme substrate binding pockets in CYP109A2 
(B), CYP109E1 (C) and Vdh (D). Apolar residues are colored in orange and polar residues in blue. 
The different BC loop regions in the three P450s (lower parts of the images) are outlined with a green 
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Figure 9. Predicted VD3-binding residues in CYP109A2, identified based on structural comparison 
with CYP109E1 and Vdh (Table 2). The residues are shown as sticks and coloured according to the 
corresponding substrate recognition site (SRS1 orange, SRS2 green, SRS3 blue, SRS4 yellow, SRS5 
pink, and SRS6 cyan). Residues overlapping in both predictions are labeled in bold. The heme group 
is shown as red coloured sticks.  
 
 
 
 
 
